GlassScriptPhysician profile
Elaine Timm
NPI 1013001338
$18,243.05
in general payments reported to CMS, 2019-2025
61 companies · $2,646 in 2025
The $2,646 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,264 · 2020: $1,654 · 2021: $2,939 · 2022: $2,664 · 2023: $2,281 · 2024: $2,794 · 2025: $2,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,721.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,564.45 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Amgen INC. | $2,116.88 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $1,452.00 | 2019-2025 | Ajovy, Austedo |
| Merz Pharmaceuticals, LLC | $1,378.74 | 2021-2025 | Xeomin |
| Ipsen Biopharmaceuticals, INC | $915.17 | 2019-2025 | Dysport |
| Jazz Pharmaceuticals INC. | $801.11 | 2021-2025 | |
| Pfizer INC. | $658.52 | 2023-2025 | |
| Merz North America, INC. | $546.71 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $535.92 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $507.92 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $494.75 | 2022 | |
| Lundbeck LLC | $482.39 | 2020-2024 | Vyepti |
| Lilly USA, LLC | $461.57 | 2019-2024 | Emgality, Reyvow |
| Upsher-Smith Laboratories LLC | $388.63 | 2019-2023 | |
| Celgene Corporation | $361.88 | 2019-2025 | Zeposia |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Timm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.